Amgen and Biosimilars: What the Biotech Giant Gets Right — and Where It Gets Tested
Amgen built its empire on one idea: biologics are the future of medicine. Patents expire. For decades, that bet paid off beautifully. Drugs like Humira, Enbrel, and Remicade generated billions in annual revenue and turned Amgen into one of the most valuable biotech companies on the planet. Here's the thing — markets open. But here's the thing about biologics — they don't stay protected forever. And biosimilars come knocking.
Counterintuitive, but true.
So what happens when the company that pioneered blockbuster biologics now has to compete with cheaper copies of its own drugs? Which means that's the question at the heart of evaluating Amgen on biosimilars. And honestly, the answer is more nuanced than most people realize.
Real talk — this step gets skipped all the time.
What Is Amgen's Role in the Biosimilars Landscape
The Innovator Problem
Amgen is, at its core, an innovator company. Even so, enbrel did the same for autoimmune and inflammatory conditions. And that means it developed the original versions of some of the most prescribed biologic drugs in the world. Humira — a treatment for autoimmune conditions like rheumatoid arthritis and Crohn's disease — was one of the best-selling drugs in human history. Remicade tackled everything from plaque psoriasis to ulcerative colitis.
Easier said than done, but still worth knowing.
These drugs are now facing (or have already faced) biosimilar competition. A biosimilar is not a generic drug — it's a biologic that's highly similar to an already-approved reference product, with no clinically meaningful differences in safety, purity, and potency. But because biologics are complex molecules made from living cells, you can't just copy them exactly the way you would a small-molecule generic. That's why they're called "biosimilars," not "generics Worth keeping that in mind. Simple as that..
Amgen's Own Biosimilar Portfolio
Here's where it gets interesting. Amgen isn't just sitting on the sidelines watching biosimilars eat into its revenue. On the flip side, the company has actively entered the biosimilar market itself. Consider this: Amjevita (adalimumab-atto) was Amgen's first approved biosimilar to Humira, launching in the U. S. in 2016. It was developed through a partnership with Samsung Bioepis, and it gave Amgen a foothold in the growing biosimilar space Most people skip this — try not to..
Since then, Amgen has expanded its biosimilar pipeline. And amgen's strategy here is clear: if you can't beat the biosimilar wave, ride it. The company has products targeting reference drugs beyond just Humira, including biosimilars to other major biologics. By developing its own biosimilars, Amgen positions itself to capture market share in the very segments where its originator drugs are losing exclusivity.
Easier said than done, but still worth knowing.
The Business Model Shift
Evaluating Amgen on biosimilars means understanding that the company is essentially running two different business models simultaneously. Worth adding: on one hand, it's still an innovator pushing novel biologics through the pipeline — things like newer antibody therapies and cell-based treatments. Looking at it differently, it's becoming a player in the value-driven biosimilar market, where pricing pressure is intense and margins are thinner Worth keeping that in mind. No workaround needed..
That dual identity creates both opportunity and risk. And it's worth unpacking both Not complicated — just consistent..
Why This Matters for Investors and the Industry
Revenue Erosion Is Real
When a blockbuster biologic loses patent protection, the revenue hit can be staggering. Analysts have estimated that Humira alone could lose billions in annual sales as biosimilars capture market share. For Amgen, which has historically depended heavily on its immunology portfolio, this erosion is not theoretical — it's already happening.
Biosimilars typically launch at 15% to 30% below the reference product's price, and that discount tends to grow over time as competition increases. For Amgen's originator drugs, this means pricing power erodes and market share shifts. Understanding how Amgen manages this transition tells you a lot about the company's long-term resilience.
Biosimilars Are a Growth Engine
On the flip side, the global biosimilar market is projected to grow substantially over the next decade. Estimates vary, but many analysts see the market reaching $50 billion or more by the early 2030s. For a company like Amgen with the scientific infrastructure, regulatory expertise, and manufacturing capability to produce biosimilars at scale, this represents a genuine growth opportunity Nothing fancy..
Amgen's partnership model — particularly with Samsung Bioepis — also matters. That's why collaborations allow the company to share development costs and risks while still gaining access to commercial revenue. That's a smart move in an industry where the cost of bringing a biosimilar to market can run into the hundreds of millions of dollars.
Quick note before moving on.
The Payer and Physician Perspective
Biosimilars aren't just a story about money — they're about access. When biosimilars enter the market, they give insurers and health systems more options, which can lower costs for patients and governments. Amgen's role in this dynamic is complicated. So as the originator company, it has an incentive to protect its market share. But as a biosimilar maker, it benefits from the broader adoption of biosimilar products Surprisingly effective..
This tension is something evaluators need to keep in mind. Amgen's incentives aren't always aligned with the pure biosimilar movement, and that creates strategic questions about how aggressively the company pushes its own biosimilar products versus its originators The details matter here..
How Amgen's Biosimilar Strategy Actually Works
The Samsung Bioepis Partnership
The Samsung Bioepis collaboration has been central to Amgen's biosimilar ambitions. Plus, under this partnership, Samsung Bioepis handles much of the early development and manufacturing, while Amgen contributes its deep knowledge of immunology, clinical development, and commercialization. The companies share profits, and Amgen gets to focus on the areas where it has the most expertise.
This model has worked well for Amjevita, which has gained traction in markets where Humira's patent protections have lapsed. It's also been extended to other biosimilar candidates, giving Amgen a diversified pipeline without requiring the company to build out every capability from scratch.
Targeting Multiple Reference Products
Amgen isn't putting all its biosimilar eggs in one basket. The company has developed or is developing biosimilars targeting several different reference products, not just Humira. This diversification helps protect against the risk that a single biosimilar market doesn't develop as expected or that competitive dynamics shift in an unexpected way.
As an example, Amgen has biosimilar candidates targeting other TNF-alpha inhibitors and other classes of biologics used in autoimmune diseases, oncology, and ophthalmology. The broader the portfolio, the more resilient the business becomes as the market evolves.
Regulatory and Manufacturing Expertise
One advantage Amgen has over smaller biotech companies entering the biosimilar space is its regulatory track record. The FDA and EMA have stringent requirements for biosimilar approval,
Regulatory and Manufacturing Expertise
The FDA and EMA have stringent requirements for biosimilar approval, demanding dependable comparability studies, extensive analytical characterization, and well‑designed clinical trials that demonstrate no clinically meaningful differences from the reference product. Amgen’s long‑standing experience with biologics—having navigated dozens of complex INDs, Phase何, and post‑marketing commitments—means it can design and execute these studies with precision. Its manufacturing facilities, many of which are certified to GMP standards for high‑volume biologic production, allow it to scale quickly once regulatory hurdles are cleared. This dual advantage reduces the time‑to‑market and the financial risk that smaller competitors often face when building new bioreactors or hiring specialized regulatory teams And it works..
Some disagree here. Fair enough.
Navigating Market Acceptance
Even with regulatory clearance, biosimilars must win the confidence of prescribers, payers, and patients. So amgen cause‑makes a concerted effort to demonstrate interchangeability in jurisdictions where it is permitted, thereby allowing pharmacists to substitute the biosimilar automatically. This leads to in the United States, the FDA’s interchangeability designation requires a rigorous set of pharmacokinetic and pharmacodynamic data. Amgen’s biosimilars have already been granted interchangeability for a few key products, lending credence to its portfolio and encouraging pharmacy benefit managers to include them in formularies. Also worth noting, Amgen’s marketing teams, accustomed to launching complex biologics, are adept at highlighting the safety, efficacy, and cost‑effectiveness of their biosimilars through evidence‑based education and real‑world data Easy to understand, harder to ignore..
Competition and Pricing Dynamics
The biosimilar market is becoming increasingly crowded, with a growing number of entrants from both established pharma and newer biotech firms. Pricing pressures are intense; payers are now demanding discounts that can erode margins. Amgen’s strategy to partner with Samsung Bioepis—who offers a strong manufacturing base in Asia—helps keep production costs lower, enabling more aggressive pricing strategies. At the same time, Amgen’s originator products, such as EYLEA and Amjevita, continue to command premium prices in niche indications, providing a financial cushion that can support the biosimilar line Small thing, real impact. Surprisingly effective..
Strategic Flexibility and Future Outlook
Amgen’s biosimilar approach is not a single‑product focus. By diversifying across several therapeutic areas—rheumatology, oncology, ophthalmology, and more—it mitigates the risk that a particular market segment stalls. The company is also exploring “next‑generation” biologics, such as biosimilars of antibody‑drug conjugates and engineered biologics, where the regulatory pathway may be similar but the commercial potential higher. In doing so, Amgen positions itself to capture a larger share of the biologics value chain, from discovery through commercialization The details matter here..
Conclusion
Amgen’s dual role as both originator and biosimilar developer presents a unique opportunity to balance innovation with cost‑efficiency. By leveraging its deep scientific expertise, regulatory pedigree, and large‑scale manufacturing capabilities—while simultaneously partnering with Samsung Bioepis to share risk and resources—Amgen is carving out a resilient biosimilar portfolio. The company’s ability to figure out pricing pressures, secure interchangeability where possible, and diversify across multiple indications will determine how well it can sustain growth in a rapidly evolving market. When all is said and done, Amgen’s biosimilar strategy illustrates a pragmatic path forward: harnessing the strengths of an established pharmaceutical behemoth to lower costs and broaden access, without sacrificing the rigorous standards that safeguard patient safety and therapeutic efficacy.
